An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Insulet Corporation (NASDAQ: PODD) plans to release its financial results for Q2 2022 on August 4, 2022, after market close. A conference call will occur at 4:30 p.m. ET the same day. Insulet is known for its Omnipod Insulin Management System, which offers a tubeless alternative for insulin delivery. The company's innovative products aim to simplify diabetes management by integrating with continuous glucose monitors for automated insulin delivery. For more details, visit the investor relations section of their website.
Positive
Innovative product portfolio focused on diabetes management
Omnipod 5 Automated Insulin Delivery System integrates with continuous glucose monitoring for improved blood sugar control
Negative
None.
ACTON, Mass.--(BUSINESS WIRE)--
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the second quarter of 2022 on August 4, 2022 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).
The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, “Events and Presentations,” and will be archived for future replay. To participate in the live call via phone, please pre-register online here to receive a telephone number and a unique passcode required to enter the call.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s latest innovation, the Omnipod® 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and is fully controlled by a compatible personal smartphone. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.
When will Insulet Corporation release its Q2 2022 financial results?
Insulet Corporation will release its Q2 2022 financial results on August 4, 2022, after the market closes.
What is the time for the conference call following Insulet's Q2 2022 results?
The conference call will be held at 4:30 p.m. ET on August 4, 2022.
What is the Omnipod Insulin Management System?
The Omnipod Insulin Management System is a tubeless insulin delivery solution that simplifies diabetes management through innovative, automated technology.
How does the Omnipod 5 system improve diabetes management?
The Omnipod 5 system integrates with continuous glucose monitors to automate insulin delivery, allowing for better blood sugar management without multiple daily injections.
